Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07247942 · ClinicalTrials.gov registry record · Phase 1
Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.
A Phase 1 study of Healthy Subjects (HS), sponsored by Wockhardt.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT07247942 is a Phase 1 study of Healthy Subjects (HS) that has completed, run by Wockhardt. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07247942, a Phase 1 study of Healthy Subjects (HS), has completed, sponsored by Wockhardt.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1, Open-label Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion in Healthy Male Subjects
Conditions Studied
Interventions
- DRUG zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour
Study Locations (1)
Wisconsin
- Covance Clinical Research Unit Inc. 3402 Kinsman Boulevard Madison, Wisconsin 53704 USA - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-12-13 |
| Est. Completion | 2019-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07247942
The ClinicalTrials.gov registry entry for NCT07247942 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wockhardt, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects (HS) appearing as the primary indexed condition, and to 1 intervention - of which zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour is the first listed.
NCT07247942 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07247942 about?
NCT07247942 is a clinical study titled "Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.". A Phase 1, Open-label Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion in Healthy Male Subjects
What is the current status of trial NCT07247942?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2017-12-13. Estimated completion is 2019-01-30.
What conditions does trial NCT07247942 study?
This clinical trial studies the following conditions: Healthy Subjects (HS).
What interventions are being tested in trial NCT07247942?
The interventions under investigation include: zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour (DRUG).
Who is sponsoring clinical trial NCT07247942?
This trial is sponsored by Wockhardt, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07247942 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.